EMA has recommended granting a conditional marketing authorisation for Rezurock (belumosudil) for the treatment of chronic graft-versus-host disease (GvHD) in adults and in children aged 12 years and older with a body weight of at least 40 kg. The medicine is to be used when other treatment options provide limited clinical benefit, are not suitable, or have been exhausted.